SCHEMBL4913600

SCHEMBL4913600

COC(=O)C1CCCC1C(=O)c1ccc(-c2ccc(NC(=O)OC(C)(C)C)c(F)c2)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.46
DGAT1 O75907 4/20 0.42
F2R P25116 1/20 0.36
DHODH Q02127 3/20 0.36
ABCB1 P08183 3/20 0.35
GPR119 Q8TDV5 1/20 0.35
NAAA Q02083 1/20 0.35
PIK3CD O00329 1/20 0.35
ABL1 P00519 1/20 0.35
EGFR P00533 1/20 0.35
KDR P35968 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CG P48736 1/20 0.35
BACE1 P56817 1/20 0.35
PRKDC P78527 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
CTPS1 P17812 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4913605 1.00 CYP17A1 (0.46) CYP17A1DGAT1F2RDHODHABCB1
SCHEMBL4920884 0.81 PDE4A (0.41) DGAT1NAAAABL1BACE1PDE4A
SCHEMBL4920876 0.81 PDE4A (0.41) DGAT1NAAAABL1BACE1PDE4A
SCHEMBL4916205 0.77 CYP17A1 (0.44) CYP17A1DGAT1PIK3CDABL1EGFR
SCHEMBL4916202 0.77 CYP17A1 (0.44) CYP17A1DGAT1PIK3CDABL1EGFR
SCHEMBL4922591 0.74 PDE4A (0.41) DGAT1GPR119NAAAPDE4APDE4B
SCHEMBL4922592 0.74 PDE4A (0.41) DGAT1GPR119NAAAPDE4APDE4B
SCHEMBL4921483 0.73 DGAT1 (0.74) DGAT1HTT
SCHEMBL4921488 0.73 DGAT1 (0.74) DGAT1HTT
SCHEMBL4925895 0.73 DGAT1 (0.74) DGAT1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064717-A1 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBOTT LABORATORIES 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064717-A1 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme DGAT1, DGAT2, DLAT CYP17A1 1433/4885DGAT1 1/4885F2R 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.